Market exclusivity allows innovator companies to recoup sizable investments in the research, development, clinical testing and bringing to market of new products.
Market exclusivity is a key incentive for pharmaceutical, agrichemical and biologics innovator companies to assume the enormous risks associated with their investments in R&D and marketing: once a new product comes to market, meaningful profits are possible only through at least some period of exclusive rights for the product.
Around the world, innovator companies use various mechanisms to achieve market exclusivity for any new product. The most pervasive mechanism is patent protection, which under the World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement ensures patent owners exclusive rights “to prevent third parties not having the owner’s consent from the acts of: making, using, offering for sale, selling, or importing” the patented product for the duration of the patent.
Other mechanisms are available in countries such as the US and in the EU, including patent term extension, data exclusivity and patent linkage.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Pharmaceutical, biotech, patent, market exclusivity